JP2018535930A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018535930A5 JP2018535930A5 JP2018515622A JP2018515622A JP2018535930A5 JP 2018535930 A5 JP2018535930 A5 JP 2018535930A5 JP 2018515622 A JP2018515622 A JP 2018515622A JP 2018515622 A JP2018515622 A JP 2018515622A JP 2018535930 A5 JP2018535930 A5 JP 2018535930A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- heteroaryl
- compound
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000001072 heteroaryl group Chemical group 0.000 claims description 65
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 52
- 125000003118 aryl group Chemical group 0.000 claims description 44
- 229910052739 hydrogen Inorganic materials 0.000 claims description 44
- 239000001257 hydrogen Substances 0.000 claims description 44
- 125000000217 alkyl group Chemical group 0.000 claims description 40
- 229910052736 halogen Inorganic materials 0.000 claims description 36
- 150000002367 halogens Chemical class 0.000 claims description 36
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 36
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 33
- 125000001424 substituent group Chemical group 0.000 claims description 28
- 229910052757 nitrogen Inorganic materials 0.000 claims description 19
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 18
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims 68
- 150000002431 hydrogen Chemical class 0.000 claims 30
- 125000004093 cyano group Chemical group *C#N 0.000 claims 18
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 10
- 101710163270 Nuclease Proteins 0.000 claims 5
- 102100026121 Flap endonuclease 1 Human genes 0.000 claims 4
- 108050002219 Flap endonuclease 1 Proteins 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 125000002947 alkylene group Chemical group 0.000 claims 3
- 125000000732 arylene group Chemical group 0.000 claims 3
- 125000002993 cycloalkylene group Chemical group 0.000 claims 3
- 125000004474 heteroalkylene group Chemical group 0.000 claims 3
- 125000005549 heteroarylene group Chemical group 0.000 claims 3
- 125000006588 heterocycloalkylene group Chemical group 0.000 claims 3
- 108010007577 Exodeoxyribonuclease I Proteins 0.000 claims 2
- 102000008779 Exonuclease 1 Human genes 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 claims 1
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 claims 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 claims 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 claims 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 claims 1
- 125000004517 1,2,5-thiadiazolyl group Chemical group 0.000 claims 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 claims 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 108010042407 Endonucleases Proteins 0.000 claims 1
- 102000004533 Endonucleases Human genes 0.000 claims 1
- 108060002716 Exonuclease Proteins 0.000 claims 1
- 102100024058 Flap endonuclease GEN homolog 1 Human genes 0.000 claims 1
- 108091006027 G proteins Proteins 0.000 claims 1
- 102000030782 GTP binding Human genes 0.000 claims 1
- 108091000058 GTP-Binding Proteins 0.000 claims 1
- 101000833646 Homo sapiens Flap endonuclease GEN homolog 1 Proteins 0.000 claims 1
- 108010091086 Recombinases Proteins 0.000 claims 1
- 102000018120 Recombinases Human genes 0.000 claims 1
- 201000006083 Xeroderma Pigmentosum Diseases 0.000 claims 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 102000013165 exonuclease Human genes 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 125000005349 heteroarylcycloalkyl group Chemical group 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 230000001024 immunotherapeutic effect Effects 0.000 claims 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 4
- 0 Cc(c(*)c(*)c(C(N1O)=O)c2NC1=O)c2S(c1ccccc1)(=O)=O Chemical compound Cc(c(*)c(*)c(C(N1O)=O)c2NC1=O)c2S(c1ccccc1)(=O)=O 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562233110P | 2015-09-25 | 2015-09-25 | |
| US62/233,110 | 2015-09-25 | ||
| PCT/IB2016/001473 WO2017051251A1 (en) | 2015-09-25 | 2016-09-26 | 3-hydroxy-quinazoline-2,4-dione derivatives and their use as nuclease modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018535930A JP2018535930A (ja) | 2018-12-06 |
| JP2018535930A5 true JP2018535930A5 (https=) | 2020-07-09 |
| JP7163180B2 JP7163180B2 (ja) | 2022-10-31 |
Family
ID=57256366
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018515622A Active JP7163180B2 (ja) | 2015-09-25 | 2016-09-26 | ３－ヒドロキシ－キナゾリン－２，４－ジオン誘導体およびヌクレアーゼ調節因子としてのこの使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11253521B2 (https=) |
| EP (1) | EP3353154B3 (https=) |
| JP (1) | JP7163180B2 (https=) |
| CN (1) | CN108430978B (https=) |
| AU (1) | AU2016325601C1 (https=) |
| CA (1) | CA2998294C (https=) |
| WO (1) | WO2017051251A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202113610D0 (en) | 2021-09-23 | 2021-11-10 | Francis Crick Institute Ltd | Novel method |
| CN114539148A (zh) * | 2022-01-25 | 2022-05-27 | 北京英飞智药科技有限公司 | 一种环状n-羟基酰亚胺类化合物及其用途 |
| CN114539080A (zh) * | 2022-03-02 | 2022-05-27 | 八叶草健康产业研究院(厦门)有限公司 | 一种2-(2-氨基-6-氯苯基)-乙酸钠的制备方法 |
| WO2023219958A2 (en) * | 2022-05-09 | 2023-11-16 | The Regents Of The University Of California | Methods for the treatment of nlrp3 related disorders |
| WO2025172707A1 (en) * | 2024-02-13 | 2025-08-21 | Merck Patent Gmbh | Heterocyclic compounds modulating exonuclease 1 (exo1) |
| WO2025172706A1 (en) * | 2024-02-13 | 2025-08-21 | Merck Patent Gmbh | Compounds modulating flap endonuclease (fen1) |
| EP4686475A1 (en) | 2024-07-31 | 2026-02-04 | Fundação D. Anna De Sommer Champalimaud E Dr. Carlos Montez Champalimaud - Centro De Investigação Da Fundação Champalimaud | Xpg inhibitors for use in the treatment of cancer |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| US5155110A (en) | 1987-10-27 | 1992-10-13 | Warner-Lambert Company | Fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition |
| CS266762B1 (cs) * | 1988-06-15 | 1990-01-12 | Pazdera Pavel | 3-Subst.ituované 4-lmlno-l ,2,3,4-tetrano-l ,2,3,4-tetra-hydrochlnazolin-2-thiony a způsob jejich přípravy |
| JP2594486B2 (ja) | 1991-01-15 | 1997-03-26 | アルコン ラボラトリーズ インコーポレイテッド | 局所的眼薬組成物 |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| DK1028950T3 (da) * | 1997-10-28 | 2003-09-01 | Warner Lambert Co | 7-substituerede quinazolin-2,4-dioner nyttige som antibakterielle midler |
| WO2001070737A2 (en) * | 2000-03-20 | 2001-09-27 | Sepracor, Inc. | Therapeutic heterocyclic compounds for the treatment of asthma and allergy and use thereof |
| US7947691B2 (en) | 2004-07-21 | 2011-05-24 | Athersys, Inc. | Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof |
| FR2962438B1 (fr) * | 2010-07-06 | 2012-08-17 | Sanofi Aventis | Derives d'indolizines, procedes de preparation et application en therapeutique |
| WO2012047993A2 (en) * | 2010-10-05 | 2012-04-12 | Regents Of The University Of Minnesota | N-hydroxypyrimidine-2,4-diones as inhibitors of hiv and hcv |
| CN105669653B (zh) | 2016-03-14 | 2018-08-21 | 山东大学 | 一种n-羟基杂环并嘧啶二酮类衍生物及其制备方法与应用 |
-
2016
- 2016-09-26 WO PCT/IB2016/001473 patent/WO2017051251A1/en not_active Ceased
- 2016-09-26 CA CA2998294A patent/CA2998294C/en active Active
- 2016-09-26 AU AU2016325601A patent/AU2016325601C1/en not_active Ceased
- 2016-09-26 EP EP16794021.2A patent/EP3353154B3/en active Active
- 2016-09-26 JP JP2018515622A patent/JP7163180B2/ja active Active
- 2016-09-26 CN CN201680068803.8A patent/CN108430978B/zh active Active
- 2016-09-26 US US15/762,527 patent/US11253521B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018535930A5 (https=) | ||
| RU2019105534A (ru) | Модуляторы хемокинового рецептора и их применение | |
| JP2024520481A5 (https=) | ||
| JP2015527355A5 (https=) | ||
| JP2020533280A5 (https=) | ||
| JP2018519357A5 (https=) | ||
| JP2021527125A5 (https=) | ||
| JP2016526558A5 (https=) | ||
| JP2024050527A5 (https=) | ||
| JP2019034943A5 (https=) | ||
| JP2025509286A5 (https=) | ||
| JP2019514883A5 (https=) | ||
| JP6359563B2 (ja) | ３−（５置換−４−オキソキナゾリン−３（４ｈ）−イル）−３−ジュウテロピペリジン−２，６−ジオン誘導体 | |
| JP2019514882A5 (https=) | ||
| RU2017121906A (ru) | Конъюгаты цистеамина и жирной кислоты и их применение в качестве активаторов аутофагии | |
| JP2015532287A5 (https=) | ||
| JP2007528417A5 (https=) | ||
| JP2008505117A5 (https=) | ||
| JP2012532112A5 (https=) | ||
| JP2016153410A5 (https=) | ||
| JP2017008098A5 (https=) | ||
| JP2018513150A5 (https=) | ||
| JP2016509591A5 (https=) | ||
| JP2008546662A5 (https=) | ||
| JP2007534695A5 (https=) |